Eli Lilly is one of the top growing stocks at the moment. Learn the reasons why this might be a stock to consider.

Anti-amyloid antibody Leqembi (lecanemab) made its EU debut in Austria yesterday and will be introduced in Germany on Monday ...

Eli Lilly & Biogen's Alzheimer's drugs may offer minimal impact despite aggressive marketing. Click here to get insights on genetics and financial implications.

CHMP recommends Lilly's donanemab for early Alzheimer's in ApoE4 heterozygotes or non-carriers. TRAILBLAZER-ALZ trials show donanemab slowed cognitive decline and reduced disease progression risk ...

The spot, which prominently utilizes a cover of “Here Comes the Sun” by The Beatles, manages to balance a message of hope with the somber nature of Alzheimer’s.

A newly approved Alzheimer’s treatment that can slow progression of the disease won’t be subsidised by the federal government ...

Eli Lilly’s Alzheimer’s disease (AD) drug Kisunla ( donanemab) has demonstrated a growing benefit over three years in ...

Anne White, a 30-year company veteran who previously led the company’s oncology unit, will step down as head of Lilly ...

Lilly to appeal as U.K. declines to endorse use of new Alzheimer’s drugs Jun. 20, 2025 7:16 AM ET Eli Lilly and Company (LLY) Stock, BIIB Stock, ESALF Stock, ESAIY Stock By: Dulan Lokuwithana ...

The US Food and Drug Administration declined to grant accelerated approval to an experimental Alzheimer's drug, donanemab, and requested additional data from Eli Lilly and Company, the drug maker. The ...

New evidence of effectiveness is cause to drop a Biden restriction on Medicare coverage for anti-amyloid treatments.

Biogen CEO Chris Viehbacher says Novo Nordisk's Alzheimer's trial success could lead to combination therapies, boosting ...